FFOX - ETF AI Analysis

Top Page

FundX Future Fund Opportunities ETF (FFOX)

Rating:59Neutral

Price Target:―

The overall rating of the FFOX ETF reflects a mix of strengths and risks across its holdings. Globus Medical and Penumbra stand out as key contributors to the fund’s rating due to their strong financial performance, strategic growth initiatives, and positive earnings calls. However, weaker holdings like Guardant Health and Ionis Pharmaceuticals, which face financial instability and valuation concerns, may have held back the fund’s score. A notable risk factor is the ETF’s exposure to companies with overbought technical conditions, which could lead to volatility.

Positive Factors

Strong Year-to-Date Performance

The ETF has delivered solid gains so far this year, reflecting positive momentum in its holdings.

Sector Diversification

The fund is spread across multiple sectors, including Technology, Health Care, and Industrials, reducing reliance on any single industry.

Healthy Top Holdings

Several top holdings, such as Guardant Health and Ionis Pharmaceuticals, have shown strong year-to-date performance, contributing to the fund’s success.

Negative Factors

High Expense Ratio

The ETF charges a relatively high expense ratio, which could eat into investor returns over time.

Geographic Concentration

The fund is heavily concentrated in U.S. companies, limiting exposure to international markets and diversification.

Underperforming Holdings

Some holdings, like Globus Medical and Penumbra, have shown weaker year-to-date performance, which may drag on overall returns.

FFOX vs. SPDR S&P 500 ETF (SPY)

AUM188.03M

RegionNorth America

Expense Ratio1.00%

Beta0.92

IssuerFundX

Inception DateJun 10, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume8,639

30 Day Avg. Volume21,004

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

33.02

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering83

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

FFOX Summary

The FundX Future Fund Opportunities ETF (FFOX) is an actively managed fund that invests in small- and mid-sized companies benefiting from major global trends like technology, sustainability, and demographic changes. It includes companies such as Guardant Health and Ionis Pharmaceuticals, focusing on sectors like technology and healthcare. This ETF offers a way to invest in innovative industries with potential for long-term growth. However, new investors should know that its performance can be volatile since it targets smaller companies and specific themes, which may be more sensitive to market changes.

How much will it cost me?The FundX Future Fund Opportunities ETF (FFOX) has an expense ratio of 1.00%, meaning you’ll pay $10 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying and investing in sectors aligned with transformative global trends.

What would affect this ETF?FFOX's focus on transformative megatrends like technology and healthcare positions it to benefit from advancements in innovation and demographic shifts, which could drive long-term growth. However, its exposure to small- and mid-cap companies may make it more sensitive to economic downturns or interest rate hikes, which can negatively impact these sectors. Additionally, regulatory changes in healthcare or technology could pose risks to its top holdings.

FFOX Top 10 Holdings

The FundX Future Fund Opportunities ETF (FFOX) leans heavily into technology and health care, with these sectors driving much of its performance. Guardant Health and Ionis Pharmaceuticals are rising stars, benefiting from strong momentum and promising growth pipelines, though valuation concerns linger. Globus Medical and Penumbra are steady contributors, bolstered by strategic initiatives and solid earnings, but overvaluation risks could weigh on future gains. With a U.S.-centric portfolio and a focus on transformative themes, FFOX is positioned to ride the wave of innovation, though its concentration in smaller names may add volatility.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
	―	7.31%	$13.73M	―	―	―
	―	4.90%	$9.21M	―	―	―
GH	Guardant Health	2.29%	$4.30M	$13.35B	187.77%	61 Neutral
IONS	Ionis Pharmaceuticals	2.12%	$3.99M	$12.77B	106.98%	61 Neutral
GMED	Globus Medical	1.92%	$3.61M	$11.90B	5.88%	82 Outperform
FTI	TechnipFMC	1.79%	$3.37M	$18.55B	49.56%	80 Outperform
PEN	Penumbra	1.77%	$3.32M	$11.25B	19.48%	78 Outperform
TIGO	Millicom International Cellular SA	1.70%	$3.20M	$8.54B	101.65%	71 Outperform
NTRA	Natera	1.66%	$3.12M	$32.58B	39.50%	73 Outperform
WMS	Advanced Drainage Systems	1.65%	$3.10M	$11.26B	15.26%	74 Outperform

FFOX Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

27.63

Positive

100DMA

27.28

Positive

200DMA

Market Momentum

MACD

0.21

Negative

RSI

59.88

Neutral

STOCH

58.27

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFOX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 27.70, equal to the 50-day MA of 27.63, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 59.88 is Neutral, neither overbought nor oversold. The STOCH value of 58.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FFOX.

FFOX Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
FFOX	―	―	$188.03M	1.00%	―
PWRD	―	―	$945.93M	0.75%	―
FEPI	―	―	$585.54M	0.65%	―
AIPI	―	―	$394.57M	0.65%	―
LFGY	―	―	$174.23M	1.02%	―
DUNK	―	―	$137.14M	0.75%	―

Performance Comparison

FFOX

FundX Future Fund Opportunities ETF

28.35

3.16

12.54%

PWRD

Tcw Transform Systems Etf

―

FEPI

REX FANG & Innovation Equity Premium Income ETF

―

AIPI

REX AI Equity Premium Income ETF

―

LFGY

YieldMax Crypto Industry & Tech Portfolio Option Income ETF

―

DUNK

Dana Unconstrained Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents